Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice

Eur J Pharmacol. 2006 Dec 3;551(1-3):98-107. doi: 10.1016/j.ejphar.2006.08.086. Epub 2006 Sep 12.

Abstract

Endothelial dysfunction is considered as a major risk factor of cardiovascular complications of type I and type II diabetes. Our previous studies have demonstrated that endothelial dysfunction in the small mesenteric arteries from 12-16 week old type II diabetic mice was associated with decreased bio-availability of nitric oxide whereas endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxation was preserved. The objective of the present study was to characterize EDHF-mediated relaxations of small mesenteric arteries from db/db mice. A depolarizing concentration of KCl or tetraethylammonium (TEA, 10 mM) significantly inhibited the EDHF-mediated relaxation to acetylcholine and bradykinin in small mesenteric arteries from both db/+ and db/db mice. Charybdotoxin or iberiotoxin alone and a combination of ouabain and barium significantly reduced the maximal relaxation to acetylcholine in small mesenteric arteries from db/db mice and charybdotoxin or iberiotoxin either alone or in combination with apamin reduced the sensitivity to the EDHF-mediated component of the relaxation response to bradykinin. 17-octadecynoic acid, but not catalase, significantly reduced the sensitivity to EDHF-mediated responses to bradykinin in db/db mice; 17-octadecynoic acid had no effect on acetylcholine-mediated relaxations. No differences were, however, detected for mRNA expression levels of calcium-activated potassium channels or connexins 37, 40, 43 and 45. Collectively, these data suggest that bradykinin-induced, EDHF-dependent relaxation in small mesenteric arteries from db/db mice is mediated via cytochrome P450 product that activates the large conductance calcium-activated potassium (BK(Ca) or Slo) channel, whereas the acetylcholine-induced, EDHF-mediated relaxation involves neither cytochrome P450 product nor hydrogen peroxide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Biological Factors / metabolism*
  • Bradykinin / pharmacology
  • Connexins / analysis
  • Cyclooxygenase Inhibitors / pharmacology
  • Cytochrome P-450 Enzyme Inhibitors
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Guanylate Cyclase / antagonists & inhibitors
  • Hydrogen Peroxide / metabolism
  • Male
  • Mesenteric Arteries / chemistry
  • Mesenteric Arteries / metabolism
  • Mesenteric Arteries / physiopathology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Mutant Strains
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels / analysis
  • Potassium Channels / drug effects
  • Potassium Channels / metabolism
  • RNA, Messenger / analysis
  • Vasodilation*
  • Vasodilator Agents / pharmacology

Substances

  • Biological Factors
  • Connexins
  • Cyclooxygenase Inhibitors
  • Cytochrome P-450 Enzyme Inhibitors
  • Enzyme Inhibitors
  • Potassium Channel Blockers
  • Potassium Channels
  • RNA, Messenger
  • Vasodilator Agents
  • endothelium-dependent hyperpolarization factor
  • Hydrogen Peroxide
  • Nitric Oxide Synthase
  • Guanylate Cyclase
  • Acetylcholine
  • Bradykinin